ATE256730T1 - Rekombinante mykobakterielle expressions-träger sowie deren verwendung - Google Patents
Rekombinante mykobakterielle expressions-träger sowie deren verwendungInfo
- Publication number
- ATE256730T1 ATE256730T1 AT89908028T AT89908028T ATE256730T1 AT E256730 T1 ATE256730 T1 AT E256730T1 AT 89908028 T AT89908028 T AT 89908028T AT 89908028 T AT89908028 T AT 89908028T AT E256730 T1 ATE256730 T1 AT E256730T1
- Authority
- AT
- Austria
- Prior art keywords
- mycobacteria
- recombinant
- mycobacterial
- vector
- coli
- Prior art date
Links
- 239000000969 carrier Substances 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 5
- 239000013612 plasmid Substances 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/32—Mycobacterium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21639088A | 1988-06-14 | 1988-06-14 | |
US22308988A | 1988-07-22 | 1988-07-22 | |
US07/361,944 US5504005A (en) | 1987-03-02 | 1989-06-05 | Recombinant mycobacterial vaccine |
PCT/US1989/002962 WO1990000594A2 (en) | 1988-07-07 | 1989-07-07 | Recombinant mycobacterial expression vehicles and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE256730T1 true ATE256730T1 (de) | 2004-01-15 |
Family
ID=27396269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT89908028T ATE256730T1 (de) | 1988-07-07 | 1989-07-07 | Rekombinante mykobakterielle expressions-träger sowie deren verwendung |
Country Status (8)
Country | Link |
---|---|
US (5) | US5504005A (de) |
EP (1) | EP0424437B1 (de) |
JP (2) | JP3485916B2 (de) |
AT (1) | ATE256730T1 (de) |
AU (1) | AU3867789A (de) |
CA (1) | CA1339526C (de) |
DE (1) | DE68929507T2 (de) |
WO (1) | WO1990000594A2 (de) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807723A (en) * | 1987-03-02 | 1998-09-15 | Whitehead Institute For Biomedical Research | Homologously recombinant slow growing mycobacteria and uses therefor |
EP0400973B1 (de) * | 1989-05-31 | 1996-07-31 | Ajinomoto Co., Inc. | Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten |
JP2903414B2 (ja) * | 1989-05-31 | 1999-06-07 | 味の素株式会社 | 抗酸菌分泌発現ベクター及び抗酸菌 |
DE69034100T2 (de) * | 1989-06-19 | 2004-06-09 | Whitehead Institute For Biomedical Research, Cambridge | Verktorvermittelte genominsertion und expression von dna in bcg |
JPH05504067A (ja) * | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
CA2045842A1 (en) * | 1990-07-16 | 1992-01-17 | William R. Jacobs | Dna capable of site-specific integration into mycobacteria |
GB9015888D0 (en) * | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
US5637303A (en) * | 1990-10-25 | 1997-06-10 | Commonwealth Scientific And Industrial Research Organisation | Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination |
AU643842B2 (en) * | 1990-10-25 | 1993-11-25 | Commonwealth Scientific And Industrial Research Organisation | Corynebacteria and related organisms as vaccine vectors |
JPH06501847A (ja) * | 1990-10-25 | 1994-03-03 | コモンウェルス サイエンティフィク アンド インダストリアルリサーチ オーガナイゼイション | ワクチンベクターとしてのコリネバクテリウム及び関連する生物 |
CA2110682A1 (en) * | 1991-06-06 | 1992-12-10 | Charles K. Stover | Induction of ctl responses to foreign antigens expressed in mycobacteria |
CA2110687A1 (en) * | 1991-06-06 | 1992-12-10 | Charles K. Stover | Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments |
US6566121B1 (en) * | 1991-06-13 | 2003-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | Insertional mutations in mycobacteria |
EP0590027A4 (de) * | 1991-06-13 | 1994-10-19 | Einstein Coll Med | Mutationen in mycobakterien durch geneinbau. |
EP0521220A1 (de) * | 1991-06-14 | 1993-01-07 | Institut Pasteur | Immunogene rekombinante Actinomycetale |
US5750384A (en) * | 1992-02-07 | 1998-05-12 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | L5 shuttle phasmids |
US6300061B1 (en) | 1992-02-07 | 2001-10-09 | Albert Einstein College Of Medicine Of Yeshiva University | Mycobacterial species-specific reporter mycobacteriophages |
US5330754A (en) * | 1992-06-29 | 1994-07-19 | Archana Kapoor | Membrane-associated immunogens of mycobacteria |
US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
US6238676B1 (en) | 1992-12-10 | 2001-05-29 | Brigham And Women's Hospital | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
DK0700445T3 (da) * | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
ATE407945T1 (de) | 1993-11-23 | 2008-09-15 | Univ California | Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung |
US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
FR2720076B1 (fr) * | 1994-05-20 | 1996-08-02 | Inst Nat Sante Rech Med | Vecteurs navettes pour l'introduction d'ADN dans des mycobactéries et utilisation de ces bactéries comme vaccins. |
US6592877B1 (en) * | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
AU774535B2 (en) * | 1995-10-20 | 2004-07-01 | Actogenix Nv | Delivery of biologically active polypeptides |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
US6221364B1 (en) * | 1996-11-12 | 2001-04-24 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacteria auxotrophic for diaminopimelate |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
CA2278116A1 (en) * | 1997-01-21 | 1998-07-23 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
WO1998035705A1 (en) * | 1997-02-18 | 1998-08-20 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
ATE327259T1 (de) | 1997-08-05 | 2006-06-15 | Stressgen Biotechnologies Corp | Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine |
EP0934421A1 (de) * | 1997-08-06 | 1999-08-11 | Laboratorio Medinfar-Produtos Farmaceuticos LDA. | Dna-integrierung in das genom von mycobakterium spp. durch trans-komplementierung mit hilfe eines zielortgerichteten integrationssystems |
CA2245408A1 (en) * | 1997-08-21 | 1999-02-21 | York University | High-throughput screens for enzyme inhibitors |
EP0902086A1 (de) * | 1997-08-22 | 1999-03-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberkolose Impfstoff |
US5972700A (en) * | 1997-09-26 | 1999-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | TM4 conditional shuttle phasmids and uses thereof |
US6387694B1 (en) * | 1998-04-03 | 2002-05-14 | Albert Einstein College Of Medicine Of Yeshiva University | Mycobacterial isocitrate lyase gene and uses thereof |
EP1105490A1 (de) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
US6497880B1 (en) * | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
AU3593200A (en) * | 1999-02-09 | 2000-08-29 | Powderject Vaccines, Inc. | (mycobacterium tuberculosis), immunization |
US8143386B2 (en) * | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
EP1196772A2 (de) | 1999-07-08 | 2002-04-17 | Stressgen Biotechnologies Corporation | Induktion einer th1-vermittelten immunantwort in vitro |
AU779978B2 (en) * | 1999-10-07 | 2005-02-24 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
CA2396384A1 (en) | 2000-01-14 | 2001-07-19 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
AU2001241738A1 (en) * | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
US6924118B2 (en) * | 2000-04-17 | 2005-08-02 | The Regents Of The University Of California | Recombinant intracellular pathogen immunogenic compositions and methods for use |
US6471967B1 (en) | 2000-04-17 | 2002-10-29 | The Regents Of The University Of California | Recombinant intracellular pathogen vaccines and methods for use |
EP1792995A3 (de) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen |
CA2408328C (en) * | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
AU2001268678B2 (en) * | 2000-06-20 | 2006-11-16 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
PT1296711E (pt) | 2000-06-26 | 2006-08-31 | Stressgen Biotechnologies Corp | E7 de vph para o tratamento do virus do papiloma humano |
ES2284681T3 (es) | 2000-08-25 | 2007-11-16 | Aventis Pasteur Limited | Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae. |
AU1120102A (en) | 2000-11-02 | 2002-05-15 | Univ Singapore | AopB gene, protein, homologs, fragments and variants thereof, and their use for cell surface display |
KR20030074787A (ko) * | 2001-02-05 | 2003-09-19 | 스트레스젠 바이오테크놀러지스 코포레이션 | B형 간염 바이러스 치료 |
US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
UA79952C2 (en) * | 2001-12-10 | 2007-08-10 | Kabulesh Mafatlal Khamar | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT |
US7026465B2 (en) * | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
US7758874B2 (en) * | 2002-02-19 | 2010-07-20 | Albert Einstein College Of Medicine Of Yeshiva University | Attenuated Mycobacterium tuberculosis vaccines |
WO2003070164A2 (en) * | 2002-02-19 | 2003-08-28 | Albert Einstein College Of Medicine Of Yeshiva University | Attenuated mycobacterium tuberculosis vaccines |
US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2003250250B2 (en) * | 2002-06-19 | 2008-02-14 | Intrexon Actobiotics Nv | Methods and means to promote gut absorption |
WO2004016280A1 (ja) * | 2002-08-16 | 2004-02-26 | Japan Science And Technology Agency | 組換えbcgワクチン |
EP1560935A2 (de) * | 2002-11-15 | 2005-08-10 | VIB vzw | Selbst-enthaldender lactobacillus strain |
CA2508375C (en) * | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
US8084041B2 (en) * | 2003-01-24 | 2011-12-27 | Albert Einstein College Of Medicine Of Yeshiva University | Use of mycrobacterial vaccines in CD4+ or CD8+ lymphocyte-deficient mammals |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
DK2206514T3 (da) | 2003-10-16 | 2014-04-22 | Univ California | Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse |
WO2007121194A1 (en) * | 2006-04-10 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
US8163294B2 (en) * | 2003-10-16 | 2012-04-24 | The Regents Of The University Of California | Growth regulatable recombinant BCG compositions |
US8383132B2 (en) * | 2003-10-16 | 2013-02-26 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20060002956A1 (en) * | 2004-04-05 | 2006-01-05 | Surber Mark W | Minicells as vaccines |
EP1846024B1 (de) * | 2005-01-12 | 2016-03-23 | Albert Einstein College of Medicine, Inc. | Auf eine wirts-apoptose einwirkende mykobakterielle mutanten |
WO2006076343A1 (en) * | 2005-01-12 | 2006-07-20 | Albert Einstein College Of Medicine Of Yeshiva University | Mycobacteria expressing hiv-1 and malaria antigens |
EP2284257A1 (de) | 2005-01-18 | 2011-02-16 | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg | Mycobakterien mit mannose-cap-mangelndem Lipoarabinomannan |
BRPI0613007A2 (pt) * | 2005-07-14 | 2016-11-29 | Basf Ag | misturas fungicidas para combater fungos nocivos fitopatogênicos, agente, processo para combater fungos nocivos fitopatogênicos, semente, e, uso dos compostos |
US8748126B2 (en) | 2005-11-29 | 2014-06-10 | Actogenix N.V. | Induction of mucosal tolerance to antigens |
WO2007067729A2 (en) | 2005-12-09 | 2007-06-14 | University Of Georgia Research Foundation, Inc. | Microbial vaccine and vaccine vector |
BRPI0706532A8 (pt) * | 2006-01-12 | 2019-01-02 | Albert Einstein College Medicine Yeshiva Univ | mutantes de micobactéria seca2 |
CN101605559B (zh) | 2007-01-25 | 2014-04-23 | 阿克图杰尼斯公司 | 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病 |
WO2009008912A2 (en) | 2007-03-19 | 2009-01-15 | Albert Einstein College Of Medicine Of Yeshiva University | Mycobacterial mutants inducing il-12 |
CN102016045A (zh) | 2007-05-02 | 2011-04-13 | 梅瑞尔有限公司 | 具有改善的表达和稳定性的dna质粒 |
US8361482B2 (en) * | 2007-11-27 | 2013-01-29 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease |
US7670609B2 (en) * | 2007-11-27 | 2010-03-02 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease |
MX2011006922A (es) | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
US20140093556A1 (en) | 2011-01-28 | 2014-04-03 | Sanofi Pasteur Sa | Immunological Compositions Against HIV |
AU2012217728B2 (en) | 2011-02-15 | 2017-04-27 | Vaxiion Therapeutics, Llc | Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
JP6193231B2 (ja) | 2011-08-08 | 2017-09-06 | チュアラボ オンコロジー, インコーポレーテッドCurelab Oncology, Inc. | がんの治療および予防のための、p62に関する方法および組成物 |
US9447449B2 (en) | 2011-10-21 | 2016-09-20 | Albert Einstein College Of Medicine, Inc. | Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria |
BR102012003790A2 (pt) | 2012-02-17 | 2014-04-22 | Fundacao Butantan | Cepa de mycobacterium recombinante, composição imunogênica e uso |
WO2014032835A1 (en) | 2012-08-31 | 2014-03-06 | Laboratorios Del Dr. Esteve, S.A. | Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine |
CA2884918C (en) | 2012-09-17 | 2019-01-08 | Novartis Tiergesundheit Ag | Salmonid alphavirus and uses thereof |
EP2914618B1 (de) | 2012-11-02 | 2017-07-26 | Novartis Tiergesundheit AG | Mit 'theiler's disease' assoziiertes flavivirus |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
CN106061501A (zh) | 2013-12-29 | 2016-10-26 | Cl昂科莱吉有限公司 | 用于治疗和预防炎症相关疾病的涉及p62/sqstm1的方法和组合物 |
DK3177644T3 (da) | 2014-08-05 | 2021-01-11 | MabQuest SA | Immunologiske reagenser, som binder til PD-1 |
JP2019509046A (ja) | 2015-12-05 | 2019-04-04 | サントル オスピタリエ ユニヴェルシテール ヴォドアCentre Hospitalier Universitaire Vaudois | Hiv結合剤 |
WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
US10774391B2 (en) * | 2016-03-31 | 2020-09-15 | University Of The Witwatersrand, Johannesburg | Genetically modified strains of mycobacterium smegmatis |
WO2018002940A1 (en) * | 2016-06-30 | 2018-01-04 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacteriophage variants having extended host-range, methods for preparation and uses thereof in transducing nucleic acids into hosts of interest |
CN111511907A (zh) | 2017-03-14 | 2020-08-07 | 加利福尼亚大学董事会 | 对病毒中免疫逃逸功能区域的全基因组鉴定 |
CN109825497A (zh) * | 2019-01-25 | 2019-05-31 | 石河子大学 | 一种新型结核杆菌融合菌株的制备方法及其应用 |
JP2022541900A (ja) | 2019-07-15 | 2022-09-28 | ローザンヌ ユニヴァーシティ ホスピタル | Hiv結合剤 |
TW202206098A (zh) | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
CN114315985A (zh) | 2020-09-29 | 2022-04-12 | 硕腾服务有限责任公司 | 减毒猪流行性腹泻病毒 |
EP4395819A1 (de) | 2021-08-31 | 2024-07-10 | Zoetis Services LLC | Abgeschwächtes alphavirus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59205983A (ja) * | 1983-04-28 | 1984-11-21 | ジエネツクス・コ−ポレイシヨン | 異種遺伝子を原核微生物で発現させる方法 |
GB8314645D0 (en) * | 1983-05-26 | 1983-06-29 | Wellcome Found | Bivalent vaccines |
US4743546A (en) * | 1985-02-13 | 1988-05-10 | Biotechnica International, Inc. | Controlled gene excision |
US4906742A (en) * | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
JP3011939B2 (ja) * | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
-
1989
- 1989-06-05 US US07/361,944 patent/US5504005A/en not_active Expired - Fee Related
- 1989-07-06 CA CA000604943A patent/CA1339526C/en not_active Expired - Fee Related
- 1989-07-07 EP EP89908028A patent/EP0424437B1/de not_active Expired - Lifetime
- 1989-07-07 JP JP50758089A patent/JP3485916B2/ja not_active Expired - Fee Related
- 1989-07-07 AT AT89908028T patent/ATE256730T1/de not_active IP Right Cessation
- 1989-07-07 DE DE68929507T patent/DE68929507T2/de not_active Expired - Fee Related
- 1989-07-07 AU AU38677/89A patent/AU3867789A/en not_active Abandoned
- 1989-07-07 WO PCT/US1989/002962 patent/WO1990000594A2/en active IP Right Grant
-
1995
- 1995-05-30 US US08/454,075 patent/US6270776B1/en not_active Expired - Fee Related
- 1995-06-05 US US08/463,942 patent/US5854055A/en not_active Expired - Lifetime
-
1998
- 1998-01-28 US US09/014,560 patent/US5968733A/en not_active Expired - Lifetime
-
1999
- 1999-05-19 US US09/314,207 patent/US6372478B1/en not_active Expired - Fee Related
-
2000
- 2000-03-15 JP JP2000072963A patent/JP2000350578A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH04500305A (ja) | 1992-01-23 |
EP0424437A1 (de) | 1991-05-02 |
US5854055A (en) | 1998-12-29 |
WO1990000594A3 (en) | 1990-05-03 |
US6372478B1 (en) | 2002-04-16 |
DE68929507T2 (de) | 2004-09-23 |
JP3485916B2 (ja) | 2004-01-13 |
AU3867789A (en) | 1990-02-05 |
US5504005A (en) | 1996-04-02 |
US6270776B1 (en) | 2001-08-07 |
WO1990000594A2 (en) | 1990-01-25 |
DE68929507D1 (de) | 2004-01-29 |
EP0424437B1 (de) | 2003-12-17 |
US5968733A (en) | 1999-10-19 |
CA1339526C (en) | 1997-11-04 |
JP2000350578A (ja) | 2000-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE256730T1 (de) | Rekombinante mykobakterielle expressions-träger sowie deren verwendung | |
KR940010865B1 (ko) | 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법 | |
Yasutomi et al. | Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. | |
Srivastava et al. | Tumor rejection antigens of chemically induced sarcomas of inbred mice. | |
EP0856059B1 (de) | Verfahren zur herstellung von rekombinanten plasmiden | |
AU5848090A (en) | Vector-mediated genomic insertion and expression of dna in bcg | |
ATE353362T1 (de) | Neuartige ctla4/cd28 liganden und deren anwendungen | |
WO1995016048A3 (en) | Recombinant protein production in bovine adenovirus expression vector system | |
DE3854840D1 (de) | Rekombinant-mykobakterielle impfstoffe | |
CA2209360A1 (en) | Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen | |
ATE181572T1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
IL133056A (en) | Polypeptide containing an immunogenic portion of an m. tuberculosis antigen, a variant thereof and pharmaceutical compositions containing same | |
CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
JP2001514000A5 (de) | ||
EP0068693A3 (de) | Herstellung eines Maul- und Klauenseuche Impfstoffes aus mikrobiellen exprimierten Antigenen | |
Büttner et al. | The photosystem I-like P840-reaction center of green S-bacteria is a homodimer | |
IL90035A (en) | Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants | |
ES555124A0 (es) | Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas | |
KR970703165A (ko) | 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections) | |
AU669483B2 (en) | Nucleotide sequences and resistance proteins cycloheximide | |
MY135991A (en) | A vaccine-induced hepatits b viral strain and uses thereof | |
AU3379693A (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
Kerksiek et al. | Variable immunodominance hierarchies for H2-M3-restricted N-formyl peptides following bacterial infection | |
KR920006503A (ko) | 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터 | |
EP1233024A3 (de) | 25466, ein Mitglied aus der Familie menschlicher Transportproteine und seine Anwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |